In colitis models, oral GDNPs 2 administration increased IEC survival and proliferation, decreased pro-inflammatory cytokines (TNF-α, IL-6, and IL-1), and increased anti-inflammatory cytokines (IL-10 and IL-22). This evidence concerns the gene IL22 and colitis.